Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 3/20 | 0.37 |
| ▸ | CDK8 | P49336 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ak-106 SCHEMBL924434 | 1.00 | AR (0.43) | ARPDE1CTRPA1CCNCCDK8 | |
| SCHEMBL925771 | 0.92 | AR (0.39) | ARPDE1CTRPA1CCNCCDK8 | |
| SCHEMBL925678 | 0.92 | USP7 (0.40) | ARPDE1CCCNCCDK8CREBBP | |
| SCHEMBL924625 | 0.92 | AR (0.41) | ARTRPA1CCNCCDK8USP7 | |
| SCHEMBL924410 | 0.92 | AR (0.42) | ARPDE1CTRPA1CCNCCDK8 | |
| SCHEMBL923765 | 0.91 | AR (0.38) | ARPDE1CTRPA1CCNCCDK8 | |
| SCHEMBL924206 | 0.91 | AR (0.38) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL923456 | 0.91 | AR (0.38) | ARPDE1CCCNCCDK8CREBBP | |
| SCHEMBL924447 | 0.91 | AR (0.38) | ARPDE1CTRPA1CCNCCDK8 | |
| SCHEMBL923929 | 0.91 | AR (0.41) | ARPDE1CTRPA1USP7FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571799-B2 | Biomarkers for determining the efficacy of immune checkpoint inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-10 | — | — | US | claimed |
| EP-4680264-A2 | INTERFERON PRODRUGS | Jazz Pharmaceuticals Ireland Limited (IE) | 2026-01-21 | — | — | EP | claimed |
| EP-4660193-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | claimed |
| EP-4126051-B1 | REDUCED CALORIC INTAKE AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS IN BREVE IFOM ETS (IT) | 2025-11-12 | — | — | EP | claimed |
| EP-4578876-A1 | BISPECIFIC ANTIBODY | ONO Pharmaceutical Co., Ltd. (JP) | 2025-07-02 | — | — | EP | claimed |
| WO-2023240058-A9 | METHOD FOR DETERMINING THE EFFICACY OF A LUNG CANCER TREATMENT COMPRISING AN ANTI-PD-L1 ANTAGONIST AND AN ANTI-TIGIT ANTAGONIST ANTIBODY | GENENTECH, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119925601-A | Application of tetrahydrobiopterin pathway as target in anti-QDPR deletion type tumor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-05-06 | — | — | CN | claimed |
| CN-119856056-A | Methods for determining the efficacy of lung cancer treatment comprising anti-PD-L1 antagonists and anti-TIGHT antagonist antibodies | 基因泰克公司 | 2025-04-18 | — | — | CN | claimed |
| EP-4537107-A2 | METHOD FOR DETERMINING THE EFFICACY OF A LUNG CANCER TREATMENT COMPRISING AN ANTI-PD-L1 ANTAGONIST AND AN ANTI-TIGIT ANTAGONIST ANTIBODY | GENENTECH, INC. (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119731207-A | Bispecific antibodies | 小野药品工业株式会社 | 2025-03-28 | — | — | CN | claimed |
| EP-4096646-A1 | METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY | GENENTECH, INC. (US) | 2022-12-07 | — | — | EP | claimed |
| CN-115315256-A | Methods of treating cancer with anti-TIGIT antagonist antibodies | 基因泰克公司 | 2022-11-08 | — | — | CN | claimed |
| US-20220283167-A1 | BIOMARKERS FOR DETERMINING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-08 | — | — | US | claimed |
| US-20220273809-A1 | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-09-01 | — | — | US | claimed |
| EP-4011391-A1 | BIOMARKER FOR ACCESSING EFFICACY OF IMMUNE CHECKPOINT INHIBITOR | ONO Pharmaceutical Co., Ltd. (JP) | 2022-06-15 | — | — | EP | claimed |
| US-20220175698-A1 | COMBINATIONS OF IADADEMSTAT FOR CANCER THERAPY | ORYZON GENOMICS SA (ES) | 2022-06-09 | — | — | US | claimed |
| EP-3999542-A1 | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | Genmab A/S (DK) | 2022-05-25 | — | — | EP | claimed |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-04-28 | — | — | US | claimed |
| CN-114206386-A | Determining biomarkers for effectiveness of immune checkpoint inhibitors | 小野药品工业株式会社 | 2022-03-18 | — | — | CN | claimed |
| EP-3946295-A1 | COMBINATIONS OF IADADEMSTAT FOR CANCER THERAPY | Oryzon Genomics, S.A. (ES) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175698-A1 | COMBINATIONS OF IADADEMSTAT FOR CANCER THERAPY | CD274, PDCD1LG2, PDCD1 | AR 1057/4885PDE1C 2423/4885TRPA1 4644/4885 |
| US-20220273809-A1 | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | CD274, PDCD1LG2, PDCD1 | AR 2188/4885PDE1C 2868/4885TRPA1 4865/4885 |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | CD274, PDCD1, PTK2 | AR 559/4885PDE1C 731/4885TRPA1 1136/4885 |
| US-12571799-B2 | Biomarkers for determining the efficacy of immune checkpoint inhibitors | CD274, PDCD1, PDCD1LG2 | AR 970/4885PDE1C 3865/4885TRPA1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.